Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sacituzumab tirumotecan versus investigator's choice non-platinum chemotherapy in previously treated advanced urothelial carcinoma
MOH_2026-02-19_015669Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in transitional cell carcinoma (TCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall survival. Started Jan 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2026-02-19_015669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-19_015669.